Low-immunogenicity AAV gene therapy vector based on polynucleotide as well as preparation method and application of low-immunogenicity AAV gene therapy vector

By using polynucleotide modification and immunomodulation modules in AAV gene therapy vectors and combining RNA editing technology, the immune response and stability of AAV vectors in vivo are solved, achieving more efficient gene therapy effects and safety.

CN119061073AInactive Publication Date: 2024-12-03瑞吉明(山东)生物科技有限公司
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411544959.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-11-01
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing AAV gene therapy vectors often trigger immune responses when used in vivo, resulting in limited therapeutic effects. The existing modification technology has problems such as large side effects, high immunogenicity, poor stability and sustained expression ability.

Method used

Using polynucleotide-based low immunogenic AAV gene therapy vector, combined with RNA editing technology through 5-methylcytosine modification, miRNA or shRNA sequence, PD-1/PD-L1 blocking peptide and other immunomodulatory modules For example, CRISPR/Cas13, low immunogenic AAV capsid protein and post-transcriptional regulatory elements are selected to reduce immune response and improve vector stability and expression ability.

Benefits of technology

Effectively reduce immune response, improve the stability and continuous expression ability of AAV gene therapy vectors in the host, reduce side effects, improve treatment effect and safety, and enhance tissue targeting and ability to penetrate the blood-brain barrier.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119061073A_ABST
    Figure CN119061073A_ABST
Patent Text Reader

Abstract

The invention relates to the field of gene therapy, in particular to a low-immunogenicity AAV gene therapy vector based on polynucleotide and a preparation method and application thereof, and the vector comprises transgene for coding therapeutic protein, modified polynucleotide, low-immunogenicity AAV capsid protein and an immunoregulation module; the transgene is disposed between inverted terminal repetitions of the AAV; the low-immunogenicity AAV capsid protein is selected from a wild type of AAV5, AAV8 or AAV9 or a modified variant of the wild type of AAV5, AAV8 or AAV9; the immunoregulation module comprises a miRNA (micro Ribonucleic Acid) or shRNA ( Through polynucleotide modification and an immunoregulation module, the immunoreaction is reduced, and the stability and continuous expression ability of the AAV gene therapy vector in a host are improved; by selecting the AAV capsid protein, the transduction efficiency of the vector in a specific tissue is improved, so that the vector can reach a target tissue more effectively.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of gene therapy, and in particular to a polynucleotide-based low-immunogenic AAV gene therapy vector and a preparation method and application thereof. Background Art

[0002] Gene therapy is an effective means of treating genetic diseases, cancer and other intractable diseases. Among them, adeno-associated virus (AAV) vectors have become a commonly used gene therapy tool due to their high efficiency and stability. However, AAV vectors often trigger immune responses when used in vivo, resulting in limited therapeutic effects. Therefore, AAV vectors usually need to be modified to reduce immune responses. Existing modification technologies have many shortcomings. For example, the use of immunosuppressants often has large side effects and reduces the therapeutic effect. The immunogenicity of the obtained AAV vectors is still very high, the degree of reduction in immune response is small, and the stability and sustained expression ability of the vectors in the host are poor. Summary of the invention

[0003] In view of the deficiencies in the prior art, the present invention provides a polynucleotide-based low-immunogenic AAV gene therapy vector and a preparation method and application thereof.

[0004] One of the purposes of the present invention is to provide a low immunogenic AAV gene therapy vector based on polynucleotides, comprising a transgene encoding a therapeutic protein, a modified polynucleotide, a low immunogenic AAV capsid protein and at least one immunomodulatory module; The transgene is placed between the inverted terminal repeats of AAV and linked to a strong promoter and polyadenylation signal; The modifications include but are not limited to 5-methylcytosine modifications; The immune regulation module includes but is not limited to miRNA or shRNA sequences, and the immune regulation module is used to inhibit key factors of the immune response in vivo.

[0005] Preferably, RNA editing technology is also included, and the RNA editing technology is used to selectively modify RNA.

[0006] Preferably, the RNA editing technology is CRISPR / Cas13.

[0007] Preferably, the AAV capsid protein with low immunogenicity is selected from the wild type or modified variants of AAV5, AAV8 or AAV9.

[0008] Preferably, the immunomodulatory module further includes the expression of an immune checkpoint inhibitor, which is a PD-1 blocking peptide or a PD-L1 blocking peptide.

[0009] Preferably, the low immunogenic AAV gene therapy vector further comprises a post-transcriptional regulatory element, wherein the post-transcriptional regulatory element is a woodchuck hepatitis virus post-transcriptional element (WPRE).

[0010] Preferably, the low immunogenicity AAV gene therapy vector also includes a chemical additive for enhancing the stability of the vector, and the chemical additive is Tween 20 or sucrose.

[0011] The second object of the present invention is to provide a method for preparing a low immunogenic AAV gene therapy vector, comprising the following steps: (a) Cloning into expression vector: The modified polynucleotide, transgene encoding therapeutic protein (containing a strong promoter and polyadenylation signal), post-transcriptional regulatory elements and AAV capsid protein are cloned into expression vector by restriction endonuclease digestion or seamless cloning technology, and the restriction endonucleases are EcoRI and / or NotI; (b) Virus packaging: Lipofectamine was used for transfection and virus packaging in HEK293 cell lines or their derivatives, with a transfection ratio of 1:2 (plasmid: transfection reagent) and a transfection time of 24 h; (c) Purification: The desired low immunogenic AAV gene therapy vector is obtained by purification through density gradient centrifugation and / or affinity chromatography.

[0012] Preferably, the chromatography purification in (c) is performed using a commercial kit for ultrafiltration purification, wherein the commercial kit comprises an Amicon Ultra-15 ultrafiltration tube, and the molecular weight cutoff of the Amicon Ultra-15 ultrafiltration tube is 100 kDa.

[0013] The third object of the present invention is to provide a low-immunogenic AAV gene therapy vector for use in the preparation of drugs for treating genetic diseases, cancer or other diseases requiring long-term gene expression.

[0014] The beneficial effects of the present invention are: 1. The present invention reduces immune response and improves the stability and sustained expression ability of AAV gene therapy vectors in the host through polynucleotide modification and immune regulation modules; wherein, chemical modification (5-methylcytosine modification) is used to reduce immune stimulation and improve RNA stability and translation efficiency; by introducing miRNA or shRNA sequences to inhibit key factors of the immune response in the body and expressing immune checkpoint inhibitors (PD-1 / PD-L1 blocking peptides), the local immune environment is regulated, the immune response is reduced, the side effects caused by the immune response during treatment are reduced, and the stability and sustained expression ability of the vector in the host are improved, thereby improving safety while ensuring the therapeutic effect.

[0015] 2. The present invention improves tissue targeting and / or the ability to penetrate the blood-brain barrier by selecting AAV capsid protein, specifically, by selecting verified wild-type AAV5, AAV8 or AAV9 or their modified variants, thereby improving the transduction efficiency of the vector in specific tissues, so that the vector can reach the target tissue more effectively and improve the therapeutic effect.

[0016] 3. The present invention can enhance the stability and translation efficiency of mRNA and improve the expression level of therapeutic proteins through post-transcriptional regulatory elements. For example, the use of WPRE post-transcriptional regulatory elements can significantly enhance the stability and translation efficiency of mRNA, thereby improving the expression level of transgenes, enhancing the expression level of therapeutic proteins, and improving the consistency and durability of therapeutic effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 This is a plasmid schematic diagram of the polynucleotide-based low-immunogenic AAV gene therapy vector used in Example 1 of the present invention; Figure 2 This is a plasmid schematic diagram of the polynucleotide-based low-immunogenic AAV gene therapy vector used in Example 2 of the present invention; Figure 3 This is a plasmid schematic diagram of the polynucleotide-based low-immunogenic AAV gene therapy vector used in Example 3 of the present invention. DETAILED DESCRIPTION

[0018] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which the invention belongs. Unless otherwise specified, "AAV" refers to adeno-associated virus (AAV), which is a vector for gene introduction; polynucleotide refers to a long-chain molecule composed of multiple nucleotide units connected by phosphodiester bonds; immunomodulatory module refers to a gene element or sequence used to regulate the host immune system; post-transcriptional regulatory element refers to a sequence that can enhance the stability and translation efficiency of post-transcriptional mRNA; 5-methylcytosine modification is a form of DNA modification in which a methyl group is added to the 5th carbon atom of cytosine.

[0019] Example 1: Figure 1 As shown, a method for preparing a polynucleotide-based low-immunogenic AAV gene therapy vector (for treating hemophilia A) comprises the following steps: 1. Construction of expression vector ① Vector selection: pAAV-CMV-BGH-polyA.

[0020] ② Cloning into expression vector: Insert the DNA sequence encoding factor VIII into a plasmid vector by digestion with restriction endonucleases (EcoRI and NotI), ensuring that the sequence is located between a strong promoter (CMV promoter) and a polyadenylation signal (BGH polyA signal), i.e., pAAV-CMV-Factor VIII-BGH-polyA; ③ Add a polynucleotide sequence modified with 5-methylcytosine near the transgene encoding factor VIII, i.e., pAAV-CMV-5mC-Factor VIII-BGH-polyA; ④ Add the post-transcriptional regulatory element (WPRE) downstream of the transgene, i.e., pAAV-CMV-5mC-Factor VIII-WPRE-BGH-polyA; ⑤Insert the immune regulation module (miRNA sequence), i.e., pAAV-CMV-5mC-Factor VIII-miRNA-WPRE-BGH-polyA; ⑥ Linearize the constructed plasmid, and then use CRISPR / Cas13 technology to modify the specific RNA sequence. After modification, use ligase to recircularize the linearized plasmid DNA to enhance its stability and translation efficiency; ⑦Clone the AAV8 capsid protein gene (wild type) into another plasmid vector, namely pHelper-AAV8.

[0021] 2. Virus packaging HEK293 cell line was selected, and Lipofectamine 3000 transfection reagent was used to co-transfect the constructed expression vector and AAV capsid protein gene plasmid into HEK293 cells, that is, pAAV-CMV-5mC-Factor Ⅷ-miRNA-WPRE-BGH-polyA and pHelper-AAV8 were co-transfected into HEK293 cells using Lipofectamine3000, and the ratio of plasmid to transfection reagent was 1:2. The cells were cultured at 37°C and 5% CO2 to allow them to express and assemble AAV virus particles. The transfection time was 24 hours; the cell culture fluid was harvested by centrifugation to collect the virus particles.

[0022] 3. Purification The cells were lysed using a lysis buffer, initially purified using an ultracentrifuge, and the viral particles were further purified using an affinity chromatography column to obtain a low-immunogenic AAV gene therapy vector.

[0023] Embodiment 2: Referring to embodiment 1, as Figure 2 As shown, a method for preparing a polynucleotide-based low immunogenic AAV gene therapy vector (for treating cystic fibrosis) comprises the following steps: 1. Construction of expression vector Vector selection: pAAV-CMV-BGH-polyA.

[0024] Restriction endonucleases: EcoRI and NotI.

[0025] Cloning into expression vector: The transgene encoding CFTR, 5-methylcytosine-modified polynucleotide, post-transcriptional regulatory element (WPRE), and AAV5 capsid gene (engineered variant) were cloned into the expression vector by restriction endonuclease digestion.

[0026] No CRISPR / Cas13 technology is used to selectively modify RNA.

[0027] Immunomodulatory module: including shRNA sequence.

[0028] The specific vector finally obtained was pAAV-CMV-5mC-CFTR-shRNA-WPRE-BGH-polyA.

[0029] 2. Virus packaging Transfected cells: HEK293 cells were transfected using Lipofectamine 3000.

[0030] Transfection ratio: 1:2 (plasmid:transfection reagent).

[0031] Transfection time: 24 hours.

[0032] 3. Purification Commercial kit: Use Amicon Ultra-15 ultrafiltration tube (molecular weight cutoff 100 kDa) for ultrafiltration purification, and add Tween20 as a chemical additive to the final virus particles to obtain the desired AAV gene therapy vector.

[0033] Embodiment 3: Referring to embodiment 1, as Figure 3 As shown, a method for preparing a polynucleotide-based low-immunogenic AAV gene therapy vector (for treating cancer) comprises the following steps: 1. Construction of expression vector Vector selection: pAAV-CMV-BGH-polyA.

[0034] Restriction endonucleases: EcoRI and NotI.

[0035] Cloning into expression vector: The transgene encoding the PD-L1 blocking peptide, the 5-methylcytosine-modified polynucleotide, the posttranscriptional regulatory element (WPRE), and the AAV9 capsid gene (wild type) were cloned into the expression vector by restriction enzyme digestion.

[0036] No CRISPR / Cas13 technology is used to selectively modify RNA.

[0037] Immunomodulatory module: includes miRNA sequences, key factors for inhibiting the immune response in vivo, and sequences encoding PD-1 blocking peptides or PD-L1 blocking peptides.

[0038] The specific vector finally obtained was pAAV-CMV-5mC-PD-L1-miRNA-WPRE-BGH-polyA.

[0039] 2. Virus packaging Transfected cells: HEK293 cells were transfected using Lipofectamine 3000.

[0040] Transfection ratio: 1:2 (plasmid:transfection reagent).

[0041] Transfection time: 24 hours.

[0042] 3. Purification Methods: The desired AAV gene therapy vector was obtained by combining ultracentrifugation and chromatography column purification and adding sucrose as a chemical additive to the final virus particles.

[0043] The AAV gene therapy vectors obtained in Examples 1-3 were subjected to relevant tests and experiments: 1. Detect the purity and titer of AAV gene therapy vectors; The purity of the purified virus particles was tested by electrophoresis, and the titer was tested by quantitative PCR; Standard: Ensure that the purity of virus particles is greater than 95% and the titer is greater than 1×10^13vg / mL.

[0044] ①Purity detection steps: Take the purified AAV virus particles (1 μL) and add an appropriate amount of electrophoresis loading buffer (5 μL); prepare a 1% agarose gel and add EB (ethidium bromide) to the gel; load the sample into the gel well and perform electrophoresis with the voltage set to 100 V for 30 min; after the electrophoresis is completed, use a UV transilluminator to observe the bands on the gel to confirm whether there is a clear single band and whether the virus particles are pure; if extra bands are observed, it means that the sample may contain impurities; to further calculate the purity, use a gel imaging system to scan the gel image, and use ImageJ software to analyze the band intensity, calculate the ratio of the main band to the total band intensity, and ensure that the purity is greater than 95%.

[0045] ②Titer detection steps: Use a standard of known concentration (plasmid DNA with a known copy number) to prepare a standard curve of a series of concentrations; take the purified AAV virus particles (100 μL) and add an appropriate amount of lysis buffer (Tris-HCl pH 8.0 and SDS); after centrifugation to remove debris, take the supernatant for subsequent operations; then use a real-time fluorescence quantitative PCR instrument for quantitative PCR; for this purpose, design specific primers targeting the conserved sequences in the vector, and set the reaction conditions according to the instrument manual; finally, calculate the number of virus particles in the sample through the standard curve, and calculate the titer to ensure that the titer is greater than 1×10^13 vg / mL (virus particles per milliliter).

[0046] As shown in Table 1 and Table 2, the experimental results show that: the purity of the AAV vectors after purification in Examples 1 to 3 is greater than 95%, and the purity of the AAV vectors before purification is 70%; the titers of the AAV vectors after purification in Examples 1 to 3 are greater than 1×10^13 vg / mL, and the titer of the AAV vectors before purification is 5×10^12 vg / mL.

[0047] Table 1 AAV gene therapy vector purity test results

[0048] Table 2 AAV gene therapy vector titer detection results

[0049] 2. Cell experiment: evaluating the expression level of the AAV virus particles of each example in cells after transfection; The purified AAV viral particles were transfected into HEK293 cells, and the expression level of the key immune factor (PD-1) was detected by Western Blot.

[0050] Experimental group: HEK293 cells were transfected with purified AAV viral particles (containing transgenes encoding factor VIII, CFTR, or PD-L1 blocking peptides).

[0051] Control group: HEK293 cells were transfected with a control vector without a transgene encoding factor VIII, CFTR, or PD-L1 blocking peptide.

[0052] ① Transfection step: Transfect the purified AAV virus particles into HEK293 cells HEK293 cells were seeded in a 6-well plate with a cell density of approximately 50% (approximately 5×10^5 cells) per well. The cells were cultured in DMEM medium containing 10% FBS and 1% antibiotics until 80%-90% confluence. An appropriate amount of purified AAV virus particles (MOI=10) were added to serum-free DMEM to prepare a transfection mixture. An appropriate amount of the transfection mixture was added to each well and gently shaken to ensure that the cells were evenly exposed to the virus particles. The cells were cultured at 37°C and 5% CO2. 24 hours after transfection, the culture medium was replaced and the cells continued to be cultured.

[0053] ②Detection step: Use Western Blot to detect the expression level of PD-1 48 hours after transfection, cells were collected and an appropriate amount of lysis buffer (RIPA buffer) was added, along with protease inhibitors. After ultrasonic disruption of cells, cell debris was removed by centrifugation, and the supernatant was taken for later use. A 10% SDS-PAGE gel was prepared, and an appropriate amount of loading buffer was added to the lysed cell sample, which was loaded after boiling for 5 minutes. Electrophoresis was performed, and the voltage was set to 80 V, which was adjusted to 100 V after the sample entered the separation gel. After electrophoresis, the protein on the gel was transferred to a PVDF membrane using a wet transfer method, and the membrane was washed with TBST. Then, the membrane was placed in a TBST solution containing 5% skimmed milk powder and blocked for 1 hour. After removing the membrane, a specific primary antibody (anti-PD-1 antibody) was added, and incubated overnight at 4°C. The next day, after washing the membrane, an HRP-labeled secondary antibody was added, and incubated at room temperature for 1 hour. Finally, the ECL luminescent solution was used for development, and the results were photographed using a gel imaging system. The band intensity was analyzed using software (ImageJ) to compare the expression levels between different samples to confirm the expression of the protein.

[0054] As shown in Table 3, the experimental results show that the PD-1 expression levels of cells transfected with the AAV virus particles of Examples 1 to 3 were all lower than 20%; the PD-1 expression level of cells transfected with the control vector was 80% (higher), which indicates that the AAV virus particles of the examples can effectively reduce the expression level of PD-1, thereby reducing the immune response and improving the therapeutic effect. Among them, due to the lack of selective modification of CRISPR / Cas13 technology, the expression levels and immune response control of Examples 2 and 3 are not as good as those of Example 1.

[0055] Table 3 Test results of PD-1 expression level of AAV gene therapy vector

[0056] The above embodiments are merely illustrative of the principles and effects of the present invention, and are not intended to limit the present invention. Any person familiar with the technology may modify or alter the above embodiments without violating the spirit and scope of the present invention. The scope of protection of the present invention is defined by the claims and their equivalents.

Claims

1. A polynucleotide-based low-immunogenic AAV gene therapy vector, characterized in that: The invention comprises a transgene encoding a therapeutic protein, a modified polynucleotide, a low-immunogenic AAV capsid protein, and at least one immunomodulatory module; The transgene is placed between the inverted terminal repeat sequences of AAV and connected to a strong promoter and a polyadenylation signal; the modification includes but is not limited to 5-methylcytosine modification; the immune regulatory module includes but is not limited to miRNA or shRNA sequences, and the immune regulatory module is used to inhibit key factors of the immune response in vivo.

2. The polynucleotide-based low immunogenic AAV gene therapy vector according to claim 1, characterized in that Also included are RNA editing technologies, which are used to selectively modify RNA.

3. The polynucleotide-based low immunogenic AAV gene therapy vector according to claim 1, characterized in that The AAV capsid protein with low immunogenicity is selected from the wild type of AAV5, AAV8 or AAV9 or its modified variants.

4. The polynucleotide-based low immunogenic AAV gene therapy vector according to claim 1, characterized in that The immunomodulatory module also includes the expression of immune checkpoint inhibitors, which are PD-1 blocking peptides or PD-L1 blocking peptides.

5. The polynucleotide-based low immunogenic AAV gene therapy vector according to claim 1, characterized in that Also included is a post-transcriptional regulatory element, which is a woodchuck hepatitis virus post-transcriptional element.

6. The polynucleotide-based low immunogenic AAV gene therapy vector according to claim 2, characterized in that: The RNA editing technology is CRISPR / Cas13 technology.

7. The polynucleotide-based low immunogenic AAV gene therapy vector according to claim 1, characterized in that: The invention also comprises a chemical additive, which is Tween 20 or sucrose.

8. A method for preparing a polynucleotide-based low-immunogenic AAV gene therapy vector according to any one of claims 1 to 7, characterized in that: The following steps are involved: (a) Cloning into an expression vector: The modified polynucleotide, the transgene encoding the therapeutic protein, the post-transcriptional regulatory elements, and the AAV capsid protein are cloned into an expression vector by restriction endonuclease digestion or seamless cloning using EcoRI and / or NotI restriction enzymes. (b) Viral packaging: HEK293 cells or their derivatives were transfected and packaged using Lipofectamine at a plasmid to transfection reagent ratio of 1:2 and a transfection time of 24 h. (c) Purification: The desired low-immunogenicity AAV gene therapy vector is obtained by purification through density gradient centrifugation and / or affinity chromatography.

9. The method for preparing a polynucleotide-based low-immunogenic AAV gene therapy vector according to claim 8, characterized in that: The chromatographic purification in step (c) is performed by ultrafiltration purification using a commercial kit, which includes an Amicon Ultra-15 ultrafiltration tube with a molecular weight cutoff of 100 kDa.

10. Use of the polynucleotide-based low-immunogenic AAV gene therapy vector according to claims 1-7 in the preparation of a drug for treating genetic diseases, cancer or other diseases requiring long-term gene expression.

Citation Information

Patent Citations

  • Gene therapy constructs, pharmaceutical compositions and methods for treating pompe disease

    CN115772520A

  • Methods of treating nervous system diseases

    CN116723868A